drugset / Trial / NCT06827145
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
Phase 2
Active not recruiting
30 enrolled
National Cancer Center, China
Avistone Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation
Timeline
- Start
- 2024-10-14
- Primary completion
- 2026-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | Vebreltinib | Small molecule | 100 mg | Oral |